Gregory T Lucier

Director Gregory T Lucier purchases 10,000 shares as stock trades well below 52-week highs amid company losses.

Gregory T Lucier, a director at Avantor, purchased shares during a period when the stock is trading substantially below its 52-week high. The company is currently unprofitable with negative annual earnings, though the latest quarter showed a return to profitability. Lucier's prior buy at this company did not work out well — the stock declined in the months that followed that purchase. His overall track record across all holdings has been mixed at best, with prior purchases frequently followed by declines. This current purchase occurs at a moment of fundamental weakness and comes after a track record of poor timing, making it difficult to interpret as a strong conviction signal. The fact that he is continuing to buy despite prior unsuccessful trades at this company suggests either underlying conviction or lack of caution, but the weight of timing evidence does not support a bullish interpretation.

Director LUCIER GREGORY T buys 15,000 shares of XRAY at $12.44 on 2026-03-09; stock down -24.0% from 52-week high; company unprofitable.

Director Lucier Gregory T purchased 15,000 shares at $12.44 on 2026-03-09, increasing his stake by 30.0% to 65,000 shares total. The transaction occurs at a material discount to the 52-week high of $16.85, with the stock currently trading -24.0% below that peak and -7.0% lower over the past 30 days. However, the company's fundamentals remain challenged: it posted a net income of $-427,000,000.00 against revenue of $904,000,000.00 in the latest quarter and reported annual revenue contraction of -3.0% on a year-over-year basis. Looking at his prior trades at XRAY specifically, the timing pattern has been mixed—just 1 of his 3 measurable prior buys at this ticker achieved positive 90-day returns. This purchase enters a volatile stock environment against a backdrop of unprofitable operations.

Director LUCIER GREGORY T buys 50,000 shares at blended $14.15 across 2 transactions, establishing initial position

Director LUCIER GREGORY T executed 2 separate purchases totaling 50,000 shares for $707,379.44 ($707.4K) on 2026-03-02 and 2026-03-03, establishing a new 50.0K share position from zero prior holdings. The stock is currently trading at $13.30, down 29.3% from its 52-week high of $18.81, though it has risen 6.7% over the past 30 days and 17.3% over 90 days. At XRAY specifically, LUCIER's prior 5 purchases show a mixed track record: only 1 of 5 prior buys produced positive 90-day returns, suggesting weak timing accuracy at this ticker historically. The company's fundamentals are strained, with latest quarterly revenue of $904,000,000.00 declining 3.0% year-over-year and full-year net income of -$427,000,000.00 reflecting ongoing unprofitability. The new purchase occurs during a recovery phase but against a backdrop of weak corporate financial performance and the insider's historically poor 90-day timing results at this specific stock.

Director Lucier buys 50,000 shares of AVTR at $9.16; stock down -49.7% from 52-week high, company unprofitable with -$711.8M annual net income.

Gregory T. Lucier, a director, purchased 50,000 shares at $9.16 on 2026-02-19, establishing an initial position worth $458,000.00. The timing comes as AVTR trades -49.7% below its 52-week high of $17.68 and has declined -24.7% over the prior 30 days, suggesting entry into a period of significant weakness. Company fundamentals are challenged: the latest quarter showed revenue of $1,623,800,000.00 but a net loss of -$711,800,000.00, with annual revenue declining -3.4% year-over-year and the company unprofitable for the full fiscal year. Lucier's cross-ticker trading history shows modest results (8 prior buys with 33.33% 90-day win rate and average 90-day return of -0.7%), providing limited evidence of prescient market timing ability. The purchase occurs against a backdrop of deteriorating stock performance and negative operating results.

Director Lucier purchased 100,000 shares across 2 transactions for $368,544.16 (+181.4% increase in holdings)

Gregory T. Lucier, a Director at Maravai LifeSciences, executed 2 separate open-market purchases totaling 100,000 shares for $368,544.16 at prices of $3.70 and $3.67, increasing his holdings from 55,123 shares to 155,123 shares (+181.4%). The company operates under a challenging backdrop: revenue declined -10.3% year-over-year, net income was $-25,556,000.00 in the latest full fiscal year, and the current share price of $3.69 sits -39.8% below the 52-week high, though it has risen +28.6% in the past 30 days. Lucier's cross-ticker track record shows 6 prior open-market purchases with a 33.33% 90-day win rate and average 90-day return of -0.7%, providing limited statistical confidence in his timing. The magnitude of this purchase relative to his prior holdings is substantial, but the company's profitability challenges and the director's modest historical accuracy create divergent signals for investors to evaluate.

Director Lucier buys 15,142 shares (15.1K) of XRAY at $16.51; holdings rise to 82.0K (+22.7%); stock down 53.2% from 52-week high, unprofitable.

Director Gregory T. Lucier purchased 15,142 shares of Dentsply Sirona at $16.51 on 2025-03-03, increasing his holdings by 22.7% to 82.0K shares, for a total value of $249,994.42. The stock currently trades at $15.99, down 53.2% from its 52-week high of $34.13 and down 19.1% over the past 30 days. The company reported a net income loss of $494.0M against revenue of $951.0M in the latest quarter, with annual revenue declining 4.3% year-over-year. Of Lucier's five prior purchases at this ticker, only two demonstrated positive 90-day returns, with an inconsistent track record at Dentsply Sirona itself. This purchase occurs into significant headwinds: the stock is under heavy downward pressure, the company is unprofitable, and Lucier's historical timing at this ticker shows mixed results, making this a routine insider acquisition lacking strong conviction signals.

Director Gregory T. Lucier buys 6,000 shares in 2 tranches for $110,128.80 avg $18.35; stock down -50.6% from 52-week high.

Director Gregory T. Lucier purchased 6,000 shares in two separate transactions on 2024-11-15 and 2024-11-18 at an average price of $18.35, expanding his holdings by 9.1% to 71,729 shares. The purchases occurred while DENTSPLY SIRONA trades at $18.46—down 50.6% from its 52-week high of $37.39 and down 25.4% over 30 days—against a backdrop of unprofitability: the company reported a net loss of $-494,000,000 in its latest quarter on revenue of $951,000,000 with only 1.1% annual revenue growth. Lucier's prior trading at XRAY shows mixed 90-day outcomes (1 of 3 prior buys with positive 90-day returns), and his cross-ticker record shows 33.33% win rate at the 90-day mark. The transaction represents open-market accumulation during a period of significant price deterioration and financial underperformance, warranting detailed review of the company's near-term operating trajectory and any non-public information about operational turnaround or asset value support that may underlie the director's decision to add to his position.

Director Gregory Lucier buys 8,212 shares of XRAY at $24.35; holds now 66,660 shares post-transaction. Stock down 38.9% from 52-week high.

Director Gregory Lucier purchased 8,212 shares at $24.35 on 2024-08-08, increasing his holdings from 58,448 to 66,660 shares (+14.0%). The purchase occurs with the stock trading 38.9% below its 52-week high of $39.49 and down 13.5% over the past 90 days. Lucier's prior buy at this ticker on 2024-05-31 had not yet matured 90 days, while his November 2023 purchase at XRAY delivered +7.4% over 90 days. The company faces headwinds: net income of $-4.0M on quarterly revenue of $984.0M, with only 1.1% annual revenue growth and the business unprofitable over the most recent full fiscal year. The timing of this purchase relative to deteriorating fundamentals and price pressure warrants monitoring of whether this reflects a contrarian view or signals deeper operational challenges.